Roche China Accelerator to aid nine local biotech startups; VerImmune, U-Synbio, Hansoh
Elise Mak · 05/20/2022
A year after its launch in Shanghai, Roche China Accelerator said it has identified nine local innovative drugmakers to join efforts with the pharma giant. More news from VerImmune, U-Synbio, Hansoh, ACEA Pharma, CANSino, Bayer.
READ MORE
AI drug discovery biotech Verge Genomics secures $98M in Series B; Skyline, Denovo, Antengene - News of the day
Elise Mak · 12/17/2021
Verge Genomics has closed a $98 million Series B financing to help advance its neurological disease portfolio into the clinic and expand its drug discovery platform, and more news from Skyline, Denovo, Antengene, Zai Lab, Hansoh, Pfizer, Numab, and Vitalgen BioPharma.
READ MORE
Qilu licenses in Arbutus' hepatitis B drug for Greater China; Hansoh, Biosion, IASO - News of the day
Elise Mak · 12/14/2021
Qilu Pharmaceutical has licensed in Arbutus Biopharma Corporation's AB-729 for the treatment or prevention of hepatitis B in Greater China, and more news from Hansoh, Biosion, IASO, Innovent, Junshi, Coherus and Antengene.
READ MORE
Hansoh’s siRNA therapeutics deals stand out in October
Minhua Chu · 11/19/2021
Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics.
READ MORE
BeiGene to "vigorously" contest BMS-Celgene's termination of Abraxane pact, and more - Daily news
Elise Mak · 10/18/2021
In an ongoing dispute surrounding Abraxane (paclitaxel), a drug that BeiGene licensed from BMS' subsidiary Celgene in 2017, the Chinese drugmaker said it intends to contest "vigorously" the termination proposed by its partner, and more news from GV20 Oncotherapy, HANSOH Pharma, Hengrui Pharma and Anticancer Bioscience.
READ MORE
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement